Company Profile
Medigen Vaccine Biologics Corporation, a biotechnology drug company provides the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan.
It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. It also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue.
Its portfolio also includes anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection, and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19. Incorporated in 2012, the company is headquartered in Zhubei, Taiwan.